A promising therapy that treats blood cancers by harnessing the power of the immune system to target and destroy cancer cells could now treat solid tumors more efficiently.
Jul 2, 2024
0
35
A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy—a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable ...
Jun 12, 2024
0
14
Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human Phase I trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope, ...
Jun 12, 2024
0
1
Transgender women are still at risk for prostate cancer. A new study led by Cedars-Sinai Cancer investigators, published in JAMA concludes that current screening guidelines could miss early-stage prostate cancer in transgender ...
Jun 26, 2024
0
8
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according ...
Jun 20, 2024
0
1
Investigators from UCLA Health found using artificial intelligence to help map out the boundaries of cancerous prostate tissue can significantly reduce the risk of underestimating the extent of prostate cancer—an advancement ...
Jun 11, 2024
0
0
New data on prolonged prostate-specific antigen (PSA) progression and adverse events grouped by safety topic of interest from the PSMAfore study underscore the statistically significant and clinically meaningful radiographic ...
Jun 10, 2024
0
0
